Affiliation:
1. Jiangsu Co-Innovation Center of Efficient Processing and Utilization of Forest Resources, Nanjing Forestry University, Nanjing 210037, China
2. Jiangsu Kanion Pharmaceutical Co., Ltd., 58 Haichang South Road, Lianyungang 222001, China
Abstract
Berberine, as a representative isoquinoline alkaloid, exhibits significant hypolipidemic activity
in both animal models and clinical trials. Recently, a large number of studies on the lipid-lowering
mechanism of berberine and studies for improving its hypolipidemic activity have been reported, but for
the most part, they have been either incomplete or not comprehensive. In addition, there have been a few
specific reviews on the lipid-reducing effect of berberine. In this paper, the physicochemical properties,
the lipid-lowering mechanism, and studies of the modification of berberine all are discussed to promote
the development of berberine as a lipid-lowering agent. Subsequently, this paper provides some insights
into the deficiencies of berberine in the study of lipid-lowering drug, and based on the situation, some
proposals are put forward.
Funder
Doctorate Fellowship Foundation of Nanjing Forestry University
Project for Young Teachers of Nanjing Forestry University
Natural Science Foundation of Jiangsu Higher Education Institutions
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,General Medicine
Cited by
31 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献